What does Vaxart do?
Vaxart, Inc. is a clinical-stage biotechnology company developing recombinant vaccines as room-temperature-stable oral tablets. Its VAAST platform combines an adenovirus type 5 vector, target antigen, encoded TLR3-agonist adjuvant and an enteric coating that releases the tablet in the small intestine. The aim is to stimulate systemic and mucosal immunity. The company’s official pipeline centers on COVID-19, norovirus and influenza prophylactic vaccines, plus a therapeutic human papillomavirus program.
Why is the oral delivery platform strategically different?
A room-temperature tablet could simplify storage and administration while avoiding needle-stick risk. Oral dosing may also support immunity at infection sites. The thesis remains unproven until Vaxart demonstrates efficacy, durability and manufacturability.
| Research dimension | Vaxart position | Why it matters |
|---|---|---|
| Industry | Clinical-stage biotechnology and vaccines | Value depends on trial outcomes and partnerships, not current product sales. |
| Platform | VAAST oral recombinant tablet | One delivery architecture can potentially support several antigens and indications. |
| Customers today | Government agencies and collaboration partners | Reported revenue is largely contract reimbursement and licensing, not recurring commercial demand. |
| End market if approved | Public-health programs, healthcare systems and vaccine channels | Commercial scale would require regulatory approval, manufacturing capacity and distribution partners. |
How does Vaxart make money before product approval?
Vaxart has no vaccine product sales. Near-term economics come from government contracts, license and collaboration revenue, and legacy non-cash royalty revenue tied to the Japanese influenza antiviral Inavir. FY2025 profit reflected reimbursed development work and collaboration accounting, not a mature vaccine franchise.
Which revenue source matters most now?
Government contracts dominate. The FY2025 Form 10-K reported $224.5 million of government-contract revenue, including $223.9 million from the ATI-RRPV award. It also recognized $10.8 million from the Dynavax collaboration and $1.9 million of non-cash Inavir-related royalty revenue.
| Revenue stream | FY2025 amount | Economic character | Key dependency |
|---|---|---|---|
| Government contracts | $224.5M | Cost reimbursement and fixed-price milestones | Award scope, eligible work, funding releases and government priorities |
| License and collaboration | $10.8M | Upfront consideration allocated to license and development obligations | Completion of the Phase 2b package and partner election |
| Future-royalty accounting | $1.9M | Non-cash revenue linked to Inavir royalties sold to HCRP | Japanese influenza season and competing antivirals |
What do the latest financial results show?
The newest period is the quarter ended March 31, 2026. Vaxart’s Q1 2026 Form 10-Q shows higher BARDA-funded and collaboration revenue with modestly lower operating expenses. Profit reflected development timing, not commercial vaccine margin.
What changed year over year?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $39.2M | $20.9M | Higher BARDA activity plus $2.8M of collaboration revenue. |
| R&D expense | $29.4M | $30.7M | COVID trial expense rose, but personnel, norovirus, manufacturing and facilities costs fell. |
| G&A expense | $4.6M | $5.1M | Lower personnel and facilities costs offset some legal and professional pressure. |
| Net income (loss) | $5.2M | ($15.6M) | Contract revenue exceeded current-period operating expense. |
| Diluted EPS | $0.02 | ($0.07) | Positive accounting earnings, with 242.2M diluted weighted-average shares in Q1 2026. |
| Operating cash flow | ($2.1M) | ($9.6M) | Working-capital timing kept cash flow below reported net income. |
Which turning points still shape Vaxart today?
Vaxart’s model reflects a platform build, a public-company combination, pandemic acceleration and a shift toward funded development plus partnering.
-
2004The predecessor was incorporated as West Coast Biologicals. The enduring strategic focus became oral recombinant vaccination.
-
2007The company adopted the Vaxart name and reincorporated in Delaware, consolidating the platform identity.
-
2018Private Vaxart completed a reverse merger with Aviragen Therapeutics, creating the present public company and adding legacy Inavir royalty economics.
-
2020–2022COVID-19 development expanded the platform’s visibility and generated early clinical evidence of systemic and mucosal responses.
-
2024BARDA-related awards funded preparation and execution of a comparative Phase 2b COVID-19 study, reducing the amount Vaxart had to finance directly.
-
2025The shares moved to OTCQX after Nasdaq delisting, while the Dynavax agreement converted part of the COVID program into a partnered option structure.
-
2026BARDA funding was resized to approximately $345M, and 12-month sentinel safety data supported tolerability while the powered main-cohort readout moved to 2027.
How important are the COVID-19 and norovirus programs?
COVID-19 is the funded value-validation program
The Phase 2b COVID-19 trial enrolled about 5,400 participants: roughly 400 in a sentinel cohort and about 5,000 in the main cohort, split approximately evenly between Vaxart’s oral candidate and a strain-matched mRNA comparator. On July 6, 2026, Vaxart reported 12-month sentinel safety results: 201 oral-vaccine recipients and 199 mRNA recipients had no vaccine-related serious adverse events or sustained vaccine-related Grade 3 or higher events. The sentinel cohort was not efficacy-powered; complete main-cohort data are anticipated in 2027.
Norovirus is the major unpartnered platform opportunity
Norovirus is strategically attractive because no vaccine was approved by a major regulator as of January 2026, and the pathogen infects the intestine—an intuitive fit for local mucosal antibodies. Vaxart has reported immune responses in adults, seniors and lactating women, including a positive relationship between maternal breast-milk IgA and infant stool IgA. Yet the next clinical step depends on a partnership or other funding, and the FDA requested new clinical data before continuing review of a proposed correlate of protection.
| Program | Stage or evidence | Current economic role | Critical next proof point |
|---|---|---|---|
| COVID-19 | Phase 2b; approximately 5,400 participants | BARDA-funded and licensed to Dynavax/Sanofi successor structure | Powered comparative safety and relative-efficacy readout in 2027 |
| Norovirus | Multiple early clinical studies; bivalent oral candidate | Unpartnered option with no approved vaccine in the market | Funding a next trial and generating FDA-requested clinical evidence |
| Seasonal influenza | Clinical evidence from earlier oral constructs | Platform extension in a crowded established market | Partnering strategy and differentiation versus injectable or intranasal products |
| Therapeutic HPV | Preclinical data; regulatory filing required before trials | Long-duration oncology option | Capital-efficient path into first-in-human development |
What gives Vaxart a competitive advantage—and where is the moat incomplete?
Vaxart’s potential moat combines platform know-how, patents, formulation experience, mucosal immunology data and trial execution. The 2025 annual filing states that the company held three U.S. patents with platform claims and more than 45 issued foreign patents related to the platform or vaccine candidates at December 31, 2025. Two U.S. patents also cover aspects of the seasonal influenza candidate and are scheduled to expire in 2027 absent extension.
The strongest resource is integrated oral-vaccine know-how
The proposition requires vector design, encoded adjuvant, enteric coating, manufacturing process, stability work and disease-specific assays. That integration may create learning advantages and partner switching costs after manufacturing transfer and regulatory investment.
The moat is not proven until efficacy and manufacturability converge
Patents do not guarantee approval or uptake. Approved injectable vaccines already have large safety databases and manufacturing networks. Vaxart must show that convenience and mucosal response translate into clinically relevant protection at acceptable cost and yield.
Who are Vaxart’s main competitors?
Competition varies by indication. COVID-19 rivals include Pfizer-BioNTech, Moderna and Novavax. Norovirus competition includes Moderna, Merck, Chinese vaccine programs and Cocrystal Pharma’s oral antiviral. Influenza is an established market with large manufacturers, while Inovio and Genexine pursue therapeutic HPV approaches.
| Competitive arena | Named competitors from Vaxart filings | Vaxart’s intended distinction | Main disadvantage |
|---|---|---|---|
| COVID-19 | Pfizer-BioNTech, Moderna, Novavax | Oral dosing, room-temperature handling and mucosal response | Competitors are approved, scaled and embedded in procurement channels. |
| Norovirus | Moderna, Merck, Chinese vaccine developers; Cocrystal antiviral | Delivery to the intestine and bivalent genogroup coverage | No approved correlate of protection and funding needed for the next trial. |
| Influenza | AstraZeneca, CSL, GSK, Merck, Pfizer, Sanofi and others | Tablet convenience and potentially broader mucosal immunity | Crowded market with annual manufacturing and strain-selection infrastructure. |
| Therapeutic HPV | Inovio, Genexine and other developers | Oral therapeutic vaccination using the same platform | Preclinical status and long oncology-development timelines. |
How financially strong is Vaxart?
Vaxart’s liquidity improved during FY2025 as government reimbursements and the Dynavax transaction supported cash generation. At December 31, 2025, cash, cash equivalents and investments totaled $63.8 million; at March 31, 2026, the balance was $61.0 million. The latest balance sheet showed no conventional funded debt, but did include leases, deferred collaboration revenue and a future-royalty liability.
Why reported profit is not the same as self-funded durability
FY2025 operating cash flow was $7.7 million versus $44.8 million of use in FY2024. Q1 2026 used $2.1 million as working capital absorbed cash; operating cash flow less equipment purchases was about negative $2.5 million. Funding timing may force equity issuance.
The June 2026 BARDA modification set total available project funding at about $345 million, down roughly $116 million from the prior scope after participant enrollment was reduced. It included about $68 million of firm fixed-price amounts and permitted release of approximately $29 million to complete the trial and exploratory analyses. That funding supports execution without eliminating financing risk.
Who owns Vaxart stock, and what does governance signal?
Vaxart has dispersed common-stock ownership rather than founder voting control. The 2025 Form 10-K amendment reported 241,973,011 shares outstanding for ownership calculations on April 24, 2026 and no stockholder qualifying above the 5% disclosure threshold in its table. Directors and executive officers as a group beneficially owned 10,277,261 shares, or 4.2%, including exercisable options.
| Holder or group | Beneficial shares | Reported percentage | Governance implication |
|---|---|---|---|
| Directors and executive officers as a group | 10,277,261 | 4.2% | Insider exposure exists, but management does not control the vote. |
| Steven Lo, CEO | 1,737,689 | Less than 1% | Most beneficial ownership consisted of options exercisable within 60 days. |
| Sean Tucker, Chief Scientific Officer | 2,156,165 | Less than 1% | Chief scientific officer ownership supports continuity without voting control. |
| 5% or greater holders in company table | None qualified | Not applicable | Ownership was fragmented. |
Why did the 2026 proxy contest matter?
The contested annual meeting exposed dissatisfaction over governance, dilution and incentives. Vaxart reached a cooperation agreement with a stockholder group on July 1, 2026, resolving the proxy contest. On July 16, stockholders elected six directors and ratified the auditor, but rejected executive compensation in a non-binding vote. The annual-meeting result suggests support for continuity alongside demands for tighter pay and capital alignment.
What opportunities and risks could change the story?
The upside case is platform validation: favorable main-cohort data could support an FDA meeting, trigger a partner election and strengthen oral delivery across programs. Dynavax paid a $25 million upfront fee and bought $5 million of Vaxart stock. If it assumes development after the data package and FDA interaction, Vaxart is due another $50 million and may qualify for up to $195 million of regulatory milestones, $425 million of sales milestones and low-to-mid-teens royalties. The amounts are contingent; Sanofi acquired Dynavax in February 2026 and inherited the agreement.
Which risks are most material?
- Binary clinical risk: the sentinel cohort was not powered for efficacy, and the main cohort may fail to show a useful comparative outcome.
- Funding concentration: FY2025 and Q1 2026 revenue depended overwhelmingly on government contracts whose scope can be reduced, suspended or terminated.
- Partner discretion: the licensee can decline to assume the COVID program or terminate under contractual provisions, eliminating expected future payments.
- Dilution and listing risk: additional capital may require equity issuance, while OTCQX trading may provide less liquidity than a major national exchange.
- Patent and manufacturing risk: some U.S. platform claims approach 2027 expiry, and commercial-scale tablet production may face cost, yield or quality problems.
- Market evolution: COVID incidence, variant selection, recommendations and procurement priorities can change before approval.
Which KPIs matter most for Vaxart valuation?
Price-to-earnings is not useful when current profit comes from development reimbursement. A DCF should separate contracted near-term cash flows from risk-adjusted program value and model future free cash flow after clinical, regulatory, partner and commercialization costs.
| KPI | Latest anchor | How to interpret it |
|---|---|---|
| Main-cohort evaluable participants | Approximately 5,000 | Retention and case accrual determine statistical power and timing. |
| Sentinel safety profile | 0 vaccine-related SAEs; 0 sustained vaccine-related Grade 3+ AEs | Supports tolerability, but does not establish comparative efficacy. |
| Government revenue share | Approximately 92.8% of Q1 2026 revenue | High concentration makes contract modifications a direct revenue driver. |
| Cash and investments | $61.0M at March 31, 2026 | Sets the time available to reach data and partnership milestones. |
| Quarterly operating cash use | $2.1M in Q1 2026 | Must be normalized for working-capital collections and funded trial timing. |
| Unbilled government receivable | $50.4M at March 31, 2026 | Collection speed affects liquidity independently of reported revenue. |
| Diluted share count | 242.2M weighted average in Q1 2026 | Future financing and equity awards can materially change per-share value. |
How should a DCF treat the collaboration?
A practical model can value the $50 million election payment, milestones and royalties as separate probability-weighted branches using assumptions for technical success, partner continuation, timing, market uptake and royalty duration. Government reimbursements should reflect authorized work and expected collections, not perpetual revenue.
What is the key takeaway from Vaxart analysis?
Vaxart is an oral-vaccine platform financed through government development, collaboration economics and capital-market access. Its tablet approach could simplify distribution while targeting mucosal immunity. The COVID-19 Phase 2b program has now produced a large comparative dataset, and the July 2026 sentinel update supports a tolerability argument. The value question remains unanswered until the powered cohort reports in 2027.
Financially, Vaxart is stronger after the BARDA award and Dynavax agreement: FY2025 revenue reached $237.3 million and Q1 2026 ended with $61.0 million of cash and investments. Yet revenue is concentrated in funded development, BARDA scope was reduced, no product is approved, and management expects to need additional capital beyond its runway.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.